Issue 6: Monoclonal Antibodies – A Hope for Fast and Safe Prevention of COVID-19

May 06, 2020

By JoAnn Suzich, PhD

Head of Research at Immunocore, Former VP of Infectious Disease and Vaccines at MedImmune & Head of Microbial Sciences at Astra Zeneca


Monoclonal antibodies (mAbs) might be particularly helpful in slowing down the spread of COVID-19 in advance of the development of an effective vaccine. Here are the steps that should be taken to accelerate their development.

Virus-neutralizing mAbs could play an important role in battling the coronavirus pandemic by bridging the gap until an effective vaccine is developed. In general, mAbs can be used therapeutically or prophylactically. Given the limited therapeutic effectiveness against various other respiratory viruses their greatest application in the current pandemic might be centered around disease prevention, in particular for critical populations. 

Monoclonal antibodies are derived from B-cells isolated from a human or animal that has developed effective immunity via infection (or in some cases vaccination). Using various methods, protective B-cells are cloned under an industrial process to produce a single monoclonal antibody at scale. MAbs can be delivered via various methods from intravenously to intramuscularly, and offer a rapid shortcut to immunological protection known as passive immunity.

The Many Advantages of Monoclonal Antibodies

MAbs offer numerous advantages in the context of a pandemic, namely that development will likely be faster than for vaccines. MAbs are highly specific, binding only to a certain viral epitope and not to human self-antigens thus limiting off-target toxicities. Working by passive immunity, monoclonal antibodies do not require induction of specific immune responses in the recipient. This makes mAbs particularly helpful in preventing disease in populations where vaccine responses are usually poor such as with the immunocompromised, the very young and aging adults.

While mAb protection is likely to be of much shorter duration than that provided by a vaccine (months versus years), and protective immunity following mAb administration is immediate. One could envision administration of a virus-neutralizing mAb to first responders and health care workers, thereby enabling them to carry out their critical work without delay. Finally, clinical studies of mAbs can provide vaccine developers with insights into one possible mechanism of protection, or alternatively, highlight things that should be avoided. 

The First Companies Move into Clinical Testing

A number of companies with profound expertise in the development of mAb therapeutics have announced candidates which will quickly move into clinical testing, among them RegeneronVir Biotechnology (in collaboration with Biogen and GSK), and Astra Zeneca. While it may be possible for researchers to find better mAbs (i.e., with greater potency or fewer development liabilities), time is critical and the search for an “ideal” mAb should not prevent development of good drug candidates currently at hand. If SARS-CoV-2 follows the same pattern as other coronaviruses that circulate in the human population, we can expect a second wave of the pandemic this fall.

Preliminary safety studies in humans in late spring and summer 2020 could pave the way for efficacy studies during the second wave, answering the question of whether SARS-CoV-2-neutralizing mAbs can protect humans against COVID-19. 

How We Can Accelerate the Development

The fact that tremendous progress has been made in developing candidate mAbs in such a short time is a testament to the ingenuity and determination of researchers engaged in this work. However, drug candidate discovery is often not the most difficult part of the development process. Progressing through safety and efficacy studies and ultimately to licensure is expensive and fraught with complications that can derail, or at least significantly delay drug approval. Given what’s at stake, it is more important than ever for companies to work together with regulatory agencies to ensure that everything possible is done to streamline the drug development process without compromising data quality. For example, given that most mAb candidates will be made in Chinese hamster ovary cells (CHO), and that there is a long history of CHO manufacture of mAbs for clinical use, perhaps companies could be permitted to make clinical trial materials using cell pools instead of purified clones, thereby shaving months off development timelines.

If the goal is to get into efficacy studies in the coming fall or winter, this is a meaningful time-saver. Likewise, there should be an openness to novel clinical trial design perhaps emulating some strategies utilized in other therapeutic areas (e.g. oncology) making it possible to quickly and seamlessly progress from early safety evaluation to efficacy. A very conservative approach is usually and appropriately taken in the development of mAbs intended for use in healthy people to prevent disease. However, the threat of an ongoing pandemic should warrant at least some more risk-taking.

We Must Begin Planning for Success

Dose selection will pose a challenge and will likely require efficacy studies to be large enough to accommodate testing of different mAb dose levels. Given that only about 1/100th the quantity of mAb in circulation makes it into a healthy lung, it might be prudent to test the highest feasible dose that can be safely administered intravenously while also testing lower dosages administered by intramuscular or subcutaneous injection. The less drug each adult requires to be protected from disease and the more convenient the route of administration, the more widespread the use of an efficacious mAb will be. In this regard, assuming one or more mAb candidates make it through clinical trials to licensure in a relatively short time span, the demand for those drugs is likely to be enormous and may quickly overwhelm manufacturing capacities. Thus, it is important to begin planning for success now – before efficacy studies are even initiated – to outline the steps that could and should be taken to increase capacity in the face of clinical and regulatory success.

MAbs can be part of the solution to the ongoing coronavirus pandemic, but this will require resourcefullness and agility. Established processes and procedures can help prevent re-inventing the wheel, while slavish adherence to routine ways of work should be avoided. The circumstances in which we find ourselves are far from usual. There is no time to spare, and certainly no time to waste.


Register for the HVP COVID Report: